Rapport Therapeutics RAPP
NASDAQ RAPP
$26.00 -3.37 (-11.47%)
As of: Oct 21, 2026 · 1:35 PM EDT

Rapport Therapeutics (RAPP) EBITDA Margin (2026)

Updated

Rapport Therapeutics (RAPP) posted EBITDA Margin of -119.94% for Q1 2026.

Analysis

Rapport Therapeutics (RAPP) EBITDA Margin (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,134.17 Bn 1,102.76 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 615.84 Bn 534.36 Bn 17.26 Bn 35.95%
3 AbbVie 500.69 Bn 473.80 Bn 12.70 Bn 49.01%
4 Merck 367.34 Bn 321.72 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.61 Bn 261.60 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.75 Bn 12.86 Bn 33.11%
7 Amgen 235.51 Bn 190.91 Bn 7.24 Bn 46.01%
8 Gilead Sciences 190.60 Bn 164.80 Bn 6.22 Bn -124.26%
9 Pfizer 169.37 Bn 116.02 Bn 10.94 Bn 39.16%
10 Rapport Therapeutics 1.23 Bn 417.07 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -119.94%
API Access

Rapport Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RAPP&period=max&api_key=YOUR_API_KEY